Astagneau P, Fleury L, Leroy S, Lucet J C, Golliot F, Régnier B, Brücker G
Inter-regional Co-ordinating Centre for Nosocomial Infection Control of Northern France (C-CLIN Paris Nord).
J Hosp Infect. 1999 Aug;42(4):303-12. doi: 10.1053/jhin.1998.0612.
An estimate of the antibiotic cost of nosocomial infections (NI) was made in a university hospital group based on data collected in adult inpatients enrolled in the French national prevalence survey in 1996. Among the 6839 study patients, 636 (9.3%) presented with at least one NI, of these, data on antimicrobial treatment were available for 480. The overall daily antibiotic cost was estimated between FF 49,439 and 103,526, resulting in FF 103 to 216 per infected patient. The most expensive antibiotic treatment was prescribed in intensive care patients, for pneumonia for device-related NI, or for multi-resistant bacterial infections. Non-documented NI represented about 20% of the overall antibiotic cost. Beta-lactam antibiotics, especially third generation cephalosporins, and parenteral fluoroquinolones were the most expensive antimicrobial drugs. The cost of antibiotic treatment for NI represents a significant part of hospital expenditure that should be reduced by better control of highly expensive prescriptions.
基于1996年法国全国患病率调查中成年住院患者收集的数据，对一家大学医院集团的医院感染（NI）抗生素成本进行了估算。在6839名研究患者中，636名（9.3%）至少出现了一次医院感染，其中480名患者有抗菌治疗数据。每日抗生素总成本估计在49439至103526法郎之间，每位感染患者的成本为103至216法郎。最昂贵的抗生素治疗用于重症监护患者、与器械相关的肺炎医院感染患者或多重耐药细菌感染患者。未记录的医院感染约占抗生素总成本的20%。β-内酰胺类抗生素，尤其是第三代头孢菌素和胃肠外氟喹诺酮类药物是最昂贵的抗菌药物。医院感染的抗生素治疗成本占医院支出的很大一部分，应通过更好地控制高成本处方来降低。
